Literature DB >> 34359596

Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors.

Matthias Christgen1, Gábor Cserni2,3, Giuseppe Floris4, Caterina Marchio5,6, Lounes Djerroudi7, Hans Kreipe1, Patrick W B Derksen8, Anne Vincent-Salomon7.   

Abstract

Invasive lobular breast cancer (ILC) is the most common special histological type of breast cancer (BC). This review recapitulates developments in the histomorphologic assessment of ILC from its beginnings with the seminal work of Foote and Stewart, which was published in 1941, until today. We discuss different concepts of ILC and their implications. These concepts include (i) BC arising from mammary lobules, (ii) BC growing in dissociated cells and single files, and (iii) BC defined as a morpho-molecular spectrum of tumors with distinct histological and molecular characteristics related to impaired cell adhesion. This review also provides a comprehensive overview of ILC variants, their histomorphology, and differential diagnosis. Furthermore, this review highlights recent advances which have contributed to a better understanding of the histomorphology of ILC, such as the role of the basal lamina component laminin, the molecular specificities of triple-negative ILC, and E-cadherin to P-cadherin expression switching as the molecular determinant of tubular elements in CDH1-deficient ILC. Last but not least, we provide a detailed account of the tumor microenvironment in ILC, including tumor infiltrating lymphocyte (TIL) levels, which are comparatively low in ILC compared to other BCs, but correlate with clinical outcome. The distinct histomorphology of ILC clearly reflects a special tumor biology. In the clinic, special treatment strategies have been established for triple-negative, HER2-positive, and ER-positive BC. Treatment specialization for patients diagnosed with ILC is just in its beginnings. Accordingly, ILC deserves greater attention as a special tumor entity in BC diagnostics, patient care, and cancer research.

Entities:  

Keywords:  HER2; LCIS; LIN; beta-catenin; p120-catenin; pleomorphic; solid; tubulolobular

Year:  2021        PMID: 34359596     DOI: 10.3390/cancers13153695

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  6 in total

1.  The Clonal Relationship Between the Ductal and Lobular Components of Mixed Ductal-Lobular Carcinomas Suggested a Ductal Origin in Most Tumors.

Authors:  Belén Pérez-Mies; Tamara Caniego-Casas; Irene Carretero-Barrio; Michele Biscuola; María A López-García; David Hardisson; Marta Rosas; María J López Rodríguez; Eva Cristóbal; David Pizarro; Juan M Rosa-Rosa; José Palacios
Journal:  Am J Surg Pathol       Date:  2022-07-25       Impact factor: 6.298

2.  Management of HR+/HER2+ lobular breast cancer and trends do not mirror better outcomes.

Authors:  Marita Yaghi; Nadeem Bilani; Barbara Dominguez; Iktej Singh Jabbal; Carlos Rivera; Maroun Bou Zerdan; Hong Li; Diana Saravia; Elizabeth Stone; Zeina Nahleh
Journal:  Breast       Date:  2022-05-25       Impact factor: 4.254

3.  Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.

Authors:  Max A K Rätze; Thijs Koorman; Thijmen Sijnesael; Blessing Bassey-Archibong; Robert van de Ven; Lotte Enserink; Daan Visser; Sridevi Jaksani; Ignacio Viciano; Elvira R M Bakker; François Richard; Andrew Tutt; Lynda O'Leary; Amanda Fitzpatrick; Pere Roca-Cusachs; Paul J van Diest; Christine Desmedt; Juliet M Daniel; Clare M Isacke; Patrick W B Derksen
Journal:  Oncogene       Date:  2022-04-18       Impact factor: 8.756

Review 4.  Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.

Authors:  George Sflomos; Koen Schipper; Thijs Koorman; Amanda Fitzpatrick; Steffi Oesterreich; Adrian V Lee; Jos Jonkers; Valerie G Brunton; Matthias Christgen; Clare Isacke; Patrick W B Derksen; Cathrin Brisken
Journal:  Cancers (Basel)       Date:  2021-10-27       Impact factor: 6.639

5.  Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma.

Authors:  Matthias Christgen; Leonie Donata Kandt; Wiebke Antonopoulos; Stephan Bartels; Mieke R Van Bockstal; Martin Bredt; Maria Jose Brito; Henriette Christgen; Cecile Colpaert; Bálint Cserni; Gábor Cserni; Maximilian E Daemmrich; Raihanatou Danebrock; Franceska Dedeurwaerdere; Carolien Hm van Deurzen; Ramona Erber; Christine Fathke; Henning Feist; Maryse Fiche; Claudia Aura Gonzalez; Natalie D Ter Hoeve; Loes Kooreman; Till Krech; Glen Kristiansen; Janina Kulka; Florian Laenger; Marcel Lafos; Ulrich Lehmann; Maria Dolores Martin-Martinez; Sophie Mueller; Enrico Pelz; Mieke Raap; Alberto Ravarino; Tanja Reineke-Plaass; Nora Schaumann; Anne-Marie Schelfhout; Maxim De Schepper; Jerome Schlue; Koen Van de Vijver; Wim Waelput; Axel Wellmann; Monika Graeser; Oleg Gluz; Sherko Kuemmel; Ulrike Nitz; Nadia Harbeck; Christine Desmedt; Giuseppe Floris; Patrick Wb Derksen; Paul J van Diest; Anne Vincent-Salomon; Hans Kreipe
Journal:  J Pathol Clin Res       Date:  2021-12-10

Review 6.  Aquaporin-5 in breast cancer.

Authors:  Malte Bystrup; Frédéric H Login; Sarannya Edamana; Signe Borgquist; Trine Tramm; Tae-Hwan Kwon; Lene N Nejsum
Journal:  APMIS       Date:  2022-02-28       Impact factor: 3.428

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.